TELA Bio (TELA) Stock: Buy, Sell, or Hold?
TELA - TELA Bio, Inc. Common Stock
$1.09
-0.05 (-4.39%)
▼
5d:
-12.1%
30d:
+32.68%
90d:
+36.25%
WAIT
LOW Confidence
Analysis Updated: Oct 6, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When TELA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TELA is down 12.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TELA is down 12.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TELA is currently trading at $1.09, which is considered fair relative to its 30-day fair value range of $0.86 to $1.28.
Technical Outlook: Technically, TELA is in a uptrend. The price is currently testing key support at $1.09. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: TELA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.08 (+91.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TELA is in a uptrend. The price is currently testing key support at $1.09. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: TELA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $2.08 (+91.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.86 -
$1.28
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.4%)
- BULLISH: Trading 91.1% below Wall St target ($2.08)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.86 -
$1.28
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.09
Resistance Level
$1.50
Current Trend
Uptrend
Technical data as of
Oct 6, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.42
Wall Street Target
$2.08
(+91.1%)
Revenue Growth (YoY)
-4.5%
Profit Margin
-51.5%
Share & Embed Analysis
Last updated: October 06, 2026 11:34 PM ET
Data refreshes hourly during market hours. Next update: 12:34 AM
Data refreshes hourly during market hours. Next update: 12:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TELA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
31 analysts |
$61 | 51 HOLD |
|
SYK
Stryker Corporation |
STRONG BUY
28 analysts |
$368 | 56 HOLD |
|
MDT
Medtronic PLC |
BUY
28 analysts |
$105 | 63 BUY |
|
PODD
Insulet Corporation |
BUY
25 analysts |
$172 | 68 BUY |
|
TNDM
Tandem Diabetes Care Inc |
BUY
24 analysts |
$28 | 60 HOLD |
